KRAS and colorectal carcinoma: This study also indicates FUBP1 is a novel and powerful oncogene for the initiation of CSCs and may provide an important prognostic factor and therapeutic target for the efficient elimination of both KRAS‐mutant and wild‐type CRC metastasis.